Eledon Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Eledon is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead candidate, AT-1501, is an anti-CD40L antibody being developed for transplant rejection, autoimmune conditions and ALS. The company acquired Anelixis in September 2020 and changed its name from Novus Therapeutics in January 2021.
Financial results and liquidity
- Revenue: None from product sales; the filing reports no product revenue.
- Operating expenses: $9.0 million, up $5.6 million from $3.4 million in Q1 2020. Research and development was $5.7 million, up $4.0 million; general and administrative expense was $3.4 million, up $1.6 million.
- Loss: Operating loss was $9.0 million versus $3.4 million. Net loss was $8.5 million versus $8.2 million. The 2021 loss included a $0.5 million income tax benefit; Q1 2020 included $4.8 million of warrant inducement expense. Basic and diluted loss per share was $0.57 versus $8.52, with weighted-average shares of 14.8 million versus 0.96 million.
- Cash flow: Operating cash use was $5.2 million versus $2.2 million. Financing used $0.45 million, primarily offering costs, compared with $5.2 million provided in Q1 2020 from warrant exercises. Cash and cash equivalents decreased $5.6 million during the quarter.
- Balance sheet at March 31, 2021: Cash and cash equivalents were $108.6 million; working capital was $106.0 million; total assets were $191.7 million; total liabilities were $7.8 million; and accumulated deficit was $88.9 million. No debt balance is reported.
- Margins: Not meaningful; the company reported no product revenue.
Material changes and business developments
- R&D spending increased principally with AT-1501 clinical-trial materials and clinical costs, consulting, personnel and stock-based compensation. G&A growth reflected higher professional fees, personnel and stock-based compensation.
- The company initiated a Phase 2a open-label ALS study in October 2020, planning approximately 54 participants, and received Health Canada clearance in November 2020 to initiate a Phase 2 islet-cell-transplant study.
- AT-1501 had completed a single-ascending-dose Phase 1 study in healthy volunteers and people with ALS. The filing says doses studied were well tolerated and reports a half-life of up to 26 days; these early findings do not establish later-stage efficacy or safety.
- Legacy ENT development was curtailed after OP0201 did not meet primary efficacy endpoints in a Phase 2a acute otitis media study in June 2020.
- Common shares outstanding were 14.3 million at March 31, 2021, compared with 15.2 million at December 31, 2020, following exchanges of common shares for preferred stock and warrants. The exchanges and preferred-stock conversion terms are relevant to potential dilution.
Outlook, risks and unusual items
- Management stated cash resources were sufficient for anticipated needs through at least 12 months from issuance of the financial statements. The company nevertheless expects continued losses and says it will need additional financing to advance development and fund operations; future funding may be unavailable or dilutive.
- No revenue or profitability guidance was provided. The company expects expenses to increase as AT-1501 development advances.
- Key risks include clinical and regulatory uncertainty, trial enrollment and execution, manufacturing dependence on third parties, COVID-19-related disruption, competition, intellectual-property protection and the need for additional capital. Management reported COVID-19-related delays in some preclinical studies and inefficiencies in trial planning, although impacts had not been material to date.
- The company reported no contingent liabilities requiring accrual at quarter-end. A legacy securities lawsuit appeal was dismissed in February 2021 after an immaterial settlement payment by the company’s insurer.
- Subsequent to quarter-end, the company amended its Irvine lease to extend it through December 31, 2022, effective October 1, 2021.
Important facts for investors to verify
- Whether AT-1501 trials meet enrollment, timing, safety and efficacy objectives, and whether the islet-cell trial proceeds as planned.
- How long the $108.6 million cash balance will fund operations as development spending rises, and the timing and terms of any additional financing.
- The fully diluted share count, including conversion of preferred stock and exercise or conversion of outstanding warrants and equity awards.
- The basis for management’s stated minimum 12-month liquidity outlook and whether COVID-19 or manufacturing constraints affect trial plans.
- Whether the company’s reported early Phase 1 tolerability findings translate into acceptable safety and efficacy in larger or longer studies.